Dr Lal PathLabs Q4 FY26: Stock hits 20% upper band

Stock reaction: upper circuit, then partial cool-off

Dr. Lal PathLabs shares touched the 20% upper circuit on the BSE at ₹1,641.7 after the company’s Q4 FY26 performance drew investor attention. The stock later pared gains and was trading 17.68% higher at ₹1,610 at 11:26 AM. The move stood out against the broader market, with the BSE Sensex up 0.97% at 77,661.29 at the same time.

Q4 FY26 revenue growth: 16.6% year-on-year

The company recorded a 16.6% year-on-year rise in revenue from operations in Q4 FY26 to ₹702 crore, compared with ₹659.8 crore in the year-ago period, as cited in the report. Separately, management commentary cited Q4 FY26 revenue of ₹703 crore, and linked the growth primarily to sample volume expansion. While the exact reported base figures vary across the provided sources, the narrative across them points to mid-teen top-line growth in the quarter.

Full-year FY26 numbers management highlighted

Management said FY26 revenue stood at ₹2,763 crore, up 12.2% year-on-year. The company attributed the full-year growth to volumes, with sample volume growth of 12.9% in Q4 and 10.4% in FY26. Management also said revenue per patient in Q4 FY26 rose to ₹956, up from ₹887 in Q4 FY25, driven by changes in test and geographic mix. Tests per patient were reported at 3.21 in Q4 FY26 compared with 3.07 in the year-ago quarter.

Profitability: EBITDA growth, margins in focus

For Q4 FY26, management reported EBITDA of ₹187 crore versus ₹169 crore in Q4 FY25, with an EBITDA margin of 26.6%. For the full year, EBITDA was reported at ₹752 crore versus ₹696 crore in FY25, with a 27.2% margin. Management also shared a margin range of 27-28% while explaining that ongoing investments in infrastructure and lab additions are part of the current cost structure.

PBT, PAT and the role of exceptional items

Management reported PBT of ₹160 crore in Q4 FY26 versus ₹154 crore in the year-ago quarter, with a 22.8% margin. Profit after tax was described in multiple ways across the supplied text, including a Q4 FY26 figure of ₹132 crore (versus ₹156 crore in Q4 FY25) and another line stating consolidated net profit fell 15.2% to ₹131.3 crore due to expenses and margin pressure.

Management also highlighted exceptional items affecting comparisons. These included a one-time cost of ₹30 crore related to the new Labour Code that was accounted for in Q3 FY26, and a ₹41 crore benefit in a prior-year quarter linked to the voluntary liquidation of Suburban Diagnostics. Excluding one-time and exceptional items, management said FY26 EBITDA margin was 28.3% and PAD margin was 19.3%, with PAD growth cited at 17.9%.

Balance sheet and working capital signals

Management said net cash and cash equivalents stood at ₹1,526 crore, positioning the company with liquidity for future growth and M&A. It also highlighted lean working capital, stating that working capital was negative by 26 days. These metrics are often tracked closely in diagnostics due to their implications for cash conversion and expansion capacity.

Dividend update: final dividend and total payout

The board approved a final dividend of ₹4 per share (40%), management said. Total dividend for the year was stated at ₹20.5 per share, with the company noting the figure reflects the adjustment after a 1:1 bonus issue in Q3 FY26.

What brokerages said: targets revised, Buy calls retained

Brokerages in the provided text stayed positive on the stock, largely retaining Buy ratings while updating target prices.

Nomura raised its target price to ₹1,860 from ₹1,800, citing an unchanged 45x March 2028 EPS of ₹41.3. It also said the stock should trade at least at the upper end of its pre-COVID valuation band of 40-45x one-year forward EPS. Emkay Global Financial Services maintained a Buy with a target of ₹1,740. JM Financial Institutional Securities retained a Buy, cutting its target marginally to ₹2,072 from ₹2,075, based on 48x FY28 EPS, and continued to flag it as a top pick in diagnostics.

Key numbers snapshot

Brokerage targets at a glance

Why the quarter mattered for the diagnostics theme

The company’s commentary repeatedly linked growth to sample volumes, a key operating driver in diagnostics. It also pointed to changes in mix, with revenue per patient rising and tests per patient trending higher in Q4. At the same time, the discussion on exceptional items and investment-led margin expectations shows why investors focused on both growth and profitability, not revenue alone.

Conclusion

Dr. Lal PathLabs’ stock move to the upper circuit followed a Q4 FY26 update that highlighted mid-teen revenue growth, steady operating metrics, and a dividend announcement. Brokerages in the supplied text broadly maintained Buy calls with updated targets. Next cues for investors are likely to come from management’s execution on volume-led growth, lab expansion, and how margins track the stated 27-28% band as investments continue.